Completed NA INTERVENTIONAL 2-arm NCT00727740

A Double-blind Study to Determine if Intraduodenal Indomethacin Can Decrease the Incidence of Post-ERCP Pancreatitis

A Prospective, Multicenter, Randomized, Double-blind Controlled Study to Determine Whether a Single Dose of Intraduodenal Indomethacin Can Decrease the Incidence and Severity of Post-ERCP Pancreatitis

Sponsor: Yale University

Conditions Pancreatitis

Interventions Indomethacin Placebo suspension

Updated 8 times since 2017 Last updated: Nov 23, 2016 Started: Aug 31, 2005 Primary completion: Aug 31, 2011 Completion: Aug 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Pancreatitis and is currently completed. Yale University leads this study, which shows 8 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2023 — Jul 2024 [monthly]

Completed NA
Dec 2022 — Jan 2023 [monthly]

Completed NA
Jan 2021 — Dec 2022 [monthly]

Completed NA

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed NA
Feb 2017 — Jun 2018 [monthly]

Completed NA

Status: Unknown Status → Completed
Jan 2017 — Feb 2017 [monthly]

Unknown Status NA

First recorded

Aug 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Yale University

Data source: Yale University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New Haven, United States